Prognostic Value of Various Immune Cells and Immunoscore in Triple-negative Breast Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Apr 24

PMID 37090736

Authors

Xinyu Ren

Yu Song

Junyi Pang

Longyun Chen

Liangrui Zhou

Zhiyong Liang

Huanwen Wu

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to evaluate the expression status and prognostic role of various immunoregulatory cells and test in triple-negative breast cancer (TNBC).

Methods: The expression of five markers (CD3/CD4/CD8/CD19/CD163) of tumor immune cells was evaluated retrospectively in tumor sections from 68 consecutive cases of TNBC by immunohistochemistry. Computational image analysis was used to quantify the density and distribution of each immune marker within the tumor region, tumor invasive margin, and expression hotspots. Immunoscores were calculated using an automated approach. Other clinical characteristics were also analyzed.

Results: For all patients, Kaplan-Meier survival analysis showed that high CD3+ signals in the tumor region (disease-free survival (DFS), =0.0014; overall survival (OS), 0.0031) and total region (DFS, 0.0014; OS, 0.0031) were significantly associated with better survival. High CD4+ levels in the tumor region and total regions were significantly associated with better survival (0.05). For Hotspot analysis, CD3+ was associated with significantly better survival for all Top1, Top2, and Top3 densities (DFS and OS, 0.05). High CD4+ levels were significantly associated with better prognosis for Top1 and Top3 densities (DFS and OS, 0.05). For stage IIB and IIIC patients, CD3+ in the tumor region and all Top hotspots was found to be significantly correlated with survival (DFS and OS, 0.05). CD4+ cells were significantly associated with survival in the tumor region, total region, and Top3 density (DFS, 0.0213; OS, 0.0728). CD8+ cells were significantly associated with survival in the invasive margin, Top2 density, and Top3 density. Spatial parameter analysis showed that high colocalization of tumor cells and immune cells (CD3+, CD4+, or CD8+) was significantly associated with patient survival.

Conclusion: Computational image analysis is a reliable tool for evaluating the density and distribution of immune regulatory cells and for calculating the Immunoscore in TNBC. The Immunoscore retains its prognostic significance in TNBC later than IIB stage breast cancer. Future studies are required to confirm its potential to predict tumor responses to chemotherapy and immune therapy.

Citing Articles

Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk.

Ren X, Zhou T, Song Y, Wu H, Chou J, Miller L Breast. 2025; 80:103889.

PMID: 39908962 PMC: 11847028. DOI: 10.1016/j.breast.2025.103889.

Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology.

Mi H, Sivagnanam S, Ho W, Zhang S, Bergman D, Deshpande A Brief Bioinform. 2024; 25(5).

PMID: 39179248 PMC: 11343572. DOI: 10.1093/bib/bbae421.

Quantifying spatial CXCL9 distribution with image analysis predicts improved prognosis of triple-negative breast cancer.

Cao X, Song Y, Wu H, Ren X, Sun Q, Liang Z Front Genet. 2024; 15:1421573.

PMID: 38957805 PMC: 11217326. DOI: 10.3389/fgene.2024.1421573.

Characteristics of mast cell infiltration in lung adenocarcinoma and its impact on prognosis.

Qiu Z, Pang G, Xu X, Lin J, Wang P Discov Oncol. 2024; 15(1):208.

PMID: 38834833 PMC: 11150364. DOI: 10.1007/s12672-024-01062-5.

The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study.

Tenggara J, Rachman A, Prihartono J, Rachmadi L, Panigoro S, Heriyanto D BMC Res Notes. 2024; 17(1):44.

PMID: 38308298 PMC: 10835864. DOI: 10.1186/s13104-024-06704-z.

References

Obeid J, Wages N, Hu Y, Deacon D, Slingluff Jr C . Heterogeneity of CD8 tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies. Cancer Immunol Immunother. 2016; 66(1):33-43. PMC: 5512540. DOI: 10.1007/s00262-016-1908-4. View

Alieva M, Leidgens V, Riemenschneider M, Klein C, Hau P, van Rheenen J . Intravital imaging of glioma border morphology reveals distinctive cellular dynamics and contribution to tumor cell invasion. Sci Rep. 2019; 9(1):2054. PMC: 6375955. DOI: 10.1038/s41598-019-38625-4. View

Denkert C, Loibl S, Noske A, Roller M, Muller B, Komor M . Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2009; 28(1):105-13. DOI: 10.1200/JCO.2009.23.7370. View

Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T . CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. Int J Mol Sci. 2020; 21(18). PMC: 7555570. DOI: 10.3390/ijms21186968. View

Angelo M, Bendall S, Finck R, Hale M, Hitzman C, Borowsky A . Multiplexed ion beam imaging of human breast tumors. Nat Med. 2014; 20(4):436-42. PMC: 4110905. DOI: 10.1038/nm.3488. View

Ancuta E, Ancuta C, Zugun-Eloae F, Iordache C, Chirieac R, Carasevici E . Predictive value of cellular immune response in cervical cancer. Rom J Morphol Embryol. 2009; 50(4):651-5. View

Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L . Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open. 2017; 2(5):e000255. PMC: 5687552. DOI: 10.1136/esmoopen-2017-000255. View

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

Harris R, Cheung A, Ng J, Laddach R, Chenoweth A, Crescioli S . Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. Cancer Res. 2021; 81(16):4290-4304. PMC: 7611538. DOI: 10.1158/0008-5472.CAN-20-3773. View

10.

Asleh K, Negri G, Spencer Miko S, Colborne S, Hughes C, Wang X . Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nat Commun. 2022; 13(1):896. PMC: 8850446. DOI: 10.1038/s41467-022-28524-0. View

11.

Jamiyan T, Kuroda H, Yamaguchi R, Abe A, Hayashi M . CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast. Virchows Arch. 2020; 477(6):767-775. PMC: 7683466. DOI: 10.1007/s00428-020-02855-z. View

12.

Kuroda H, Jamiyan T, Yamaguchi R, Kakumoto A, Abe A, Harada O . Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer. Breast Cancer. 2021; 28(4):904-914. PMC: 8213582. DOI: 10.1007/s12282-021-01227-y. View

13.

Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z . Single-cell and spatial analysis reveal interaction of FAP fibroblasts and SPP1 macrophages in colorectal cancer. Nat Commun. 2022; 13(1):1742. PMC: 8976074. DOI: 10.1038/s41467-022-29366-6. View

14.

Taube J, Galon J, Sholl L, Rodig S, Cottrell T, Giraldo N . Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2017; 31(2):214-234. PMC: 6132263. DOI: 10.1038/modpathol.2017.156. View

15.

McIntire P, Irshaid L, Liu Y, Chen Z, Menken F, Nowak E . Hot Spot and Whole-Tumor Enumeration of CD8 Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer. Clin Breast Cancer. 2018; 18(6):451-458.e1. DOI: 10.1016/j.clbc.2018.04.019. View

16.

Ren X, Yuan L, Shen S, Wu H, Lu J, Liang Z . c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer. Tumour Biol. 2016; 37(8):11385-95. DOI: 10.1007/s13277-016-5010-5. View

17.

Gomez-Macias G, Molinar-Flores G, Lopez-Garcia C, Santuario-Facio S, Decanini-Arcaute H, Valero-Elizondo J . Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization. Oncol Lett. 2020; 20(5):140. PMC: 7471657. DOI: 10.3892/ol.2020.12000. View

18.

Mani N, Schalper K, Hatzis C, Saglam O, Tavassoli F, Butler M . Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Res. 2016; 18(1):78. PMC: 4966732. DOI: 10.1186/s13058-016-0737-x. View

19.

Sinicrope F, Rego R, Ansell S, Knutson K, Foster N, Sargent D . Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009; 137(4):1270-9. PMC: 2873775. DOI: 10.1053/j.gastro.2009.06.053. View

20.

Church S, Galon J . Regulation of CTL Infiltration Within the Tumor Microenvironment. Adv Exp Med Biol. 2017; 1036:33-49. DOI: 10.1007/978-3-319-67577-0_3. View